Add more subjects after a failed BE study of a HVD [Study As­sess­ment]

posted by wxp  – China, 2013-05-28 07:13 (4774 d 07:28 ago) – Posting: # 10668
Views: 16,461

❝ ... Translating statistics into simple words: You have already “consumed” the entire 5% in the first study and nothing is “left” for the add-on.

❝ Some remarks for the future:Always plan for the PK metric with the higher CV (in most cases Cmax)...


Thank you, Helmut, for your explanation and answers to my questions. I learnt a lot from the failed BE study. It is worth the time to make a deliberate plan (protocol) before the study.

❝ ... You would need a replicate design (preferably a full replicate: RTR|TRT or RTRT|TRTR). For the required sample sizes see sampleN.RSABE (FDA) and sampleN.scABEL (EMA).


I tried both with CV=0.68. 42 subjects are needed for EMA, while only 27 subjects are needed for FDA. We plan to redo the BE study with a RSABE or SCABEL design.

Learn from the failed study. Did you sample frequently enough in order to “catch” Cmax in all subjects? This is a very important aspect especially for delayed release formulations...


It was a BE study of an old drug's conventional tablet. We sampled frequently enough to "catch" the Cmax. :-)

Thanks a lot for the slides and references.

Best regards,

Xipei
China

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
213 visitors (0 registered, 213 guests [including 108 identified bots]).
Forum time: 14:42 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5